SNX-5422 is under clinical development by Esanex and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect SNX-5422’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SNX-5422 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
SNX-5422 (PF-4929113) is under development for the treatment of patients with solid tumors, prostate cancer, lung adenocarcinoma, blood cancer (refractory hematological malignancies) including non-hodgkin's lymphoma, and pancreatic tumor, thyroid cancer, small-cell lung cancer, non-small cell lung cancer. SNX-5422 is administered through oral route in the form of capsule. It is a bioavailable mesylate salt of a synthetic prodrug that acts by targeting human heat-shock protein 90 (Hsp90). The drug candidate was also under development for lymphoma and non-Hodgkin lymphoma and HER2 positive cancers (metastatic breast cancer, non-small cell lung cancer, urothelial cancer, gastrointestinal tumor and gastroesophageal carcinomas) and chronic lymphocytic leukemia, metastatic renal cell carcinoma and neuroendocrine tumors.
Quick View SNX-5422 LOA Data
|Highest Development Stage|